ObjectiveTo explore the effect of zoledronate (ZOL) on the osteoclast adhesion and expression of integrin αvand β3in vitro.MethodsMice RAW264.7 cells were used for osteoclast differentiationin vitro, and osteoclastogenesis was examined by tartrate-resistant acid phosphatase (TRAP) staining and dentin resorption lacunae examination. The cells were then divided into 2 groups, the control group and ZOL treatment group (treated with 1×10-6mol·L-1ZOL for 2 d). The adhesion ability of osteoclasts and mRNA and the protein expressions of integrin αvand β3were examined by crystal violet staining, real-time fluorescence quantitative polymerase chain reaction, Western blot analysis, and immunofluorescent chemistry.ResultsTRAP staining and dentin resorption lacunae examination revealed the formation of multi-nuclear osteoclasts. ZOL treatment significantly decreased the adhesion ability of osteoclasts (Pvand β3were 0.66±0.05 and 0.59±0.08, respectively. In the control group, the mRNA levels of integrin αvand β3were 1.01±0.01 and 1.01±0.02, respectively; these values were higher than those in the ZOL-treated group (Pvand β3in the ZOL-treated group (31 934.84±112.91 and 18 812.79±194.13) was downregulated by approximately 39.19% and 40.17%, respectively, compared with those in the control group (52 517.81±211.72 and 31 441.93±456.87) (Pvand β3in the ZOL-treated group (9.491±0.748 and 4.744±0.759) were also significantly decreased compared with those in the control group (15.159±1.143 and 11.418±1.095) (PConclusionZOL significantly inhibits osteoclast adhesion and downregulates integrin αvand β3expression, thus contributing to the ZOL-induced inhibition of osteoclastmediated bone resorption.
